Navigation Links
Hard To Treat Diseases (HTDS) Announces Initial Research Results on Potential MS Therapy
Date:2/2/2009

Research results with animal testing encouraging

BELGRADE, Serbia, Feb. 2 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) www.htdsmedical.com announced the results of preliminary testing of a potential treatment for Multiple Sclerosis.

Testing involved the use of a combination of drugs; ribavirin and tiazofurin on animal test subjects. Administration of ribavirin and tiazofurin in combination attenuated or weakened the proliferation of autoreactive T lymphocytes and their infiltration into the nervous tissue that are involved in the destruction of myelin, oligodendrocytes and axons associated with MS. The tests succeeded in decreasing clinical symptoms and duration of the disease induced in experimental animals. These results are encouraging for the future MS therapy.

Also encouraging is the fact that the two drugs in question are currently used in treatment or undergoing clinical trials in relation to the treatment of other diseases. In particular, ribavirin is already in use in human clinical practice as an antiviral drug (VIRAZOL), and is very successful in treatment of respiratory syncicial virus in children, hepatitis C, SARS and HIV. Tiazofurin is in phase II of clinical trials as an anticancer drug.

Multiple sclerosis is a chronic disease with severe neurological symptoms, which often leads to complete disability and death. To date there is no suitable therapy for this heavy neurological disorder.

The company will provide further details as they become available.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.

Get the Facts Right. The issuer works hard to continue to keep our shareholders informed, and news is updated frequently via Press Releases, Pink Sheet filings (www.pinksheets.com), and updates to our websites. Other websites not sponsored, or recognized by the Company may provide misleading or disinformation to investors in order to manipulate trading patterns for a given stock. Always look for original content from trusted sources, rather than relying on 'excerpts' or discussion boards that may not give you the whole story. The Securities and Exchange Commission requires financial institutions or brokerage firms to provide their clients with documentation describing the risks of investing in penny stocks.

CONTACT: For scientific dialogue and inquiry only Andrea can be reached via e-mail at azconsulting2001@gmail.com; For any corporate matters the readers should contact the company directly at corporate@htdsmedical.com


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Less Than Two-Thirds of Surveyed Pharmacy Directors Expect to Reimburse Both Onglyza and Alogliptin Once They are Available for the Treatment of Type 2 Diabetes
2. Top Belgian Cancer Center Becomes First in Country to Introduce RapidArc Radiotherapy Treatments From Varian Medical Systems
3. Aggressive Treatment Effective in Kids Brain Cancer
4. The American Academy of Periodontology issues statement on periodontal treatment during pregnancy
5. Drug combinations key in treating neurodegenerative diseases
6. GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer
7. Under-Treatment of Pain Exacerbated by Public Perceptions of Medicines and Safety
8. Gum Disease Treatment Doesnt Cut Preterm Birth Risk
9. Process found to play role in rheumatoid arthritis could lead to new treatment
10. Alliance of Experts Created to Help Raise Awareness of Best Practices in Diabetes Treatment
11. Novartis Oncology Launches GIST Alliance™ for Healthcare Professionals Treating Gastrointestinal Stromal Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2016)... Cary, North Carolina (PRWEB) , ... May 29, 2016 , ... ... KP-400L wide jaw clipper that has been available via Amazon.com. This new ... who have thick nails. , The jaw opening is approximately 4mm and the actual ...
(Date:5/29/2016)... ... May 29, 2016 , ... "With 30 unique self-animating ... user control the style of their project," said Christina Austin - CEO of Pixel ... web-themed intros created exclusively for use in Final Cut Pro X. Pixel Film Studios’ ...
(Date:5/28/2016)... ... 2016 , ... "Color Grading media can be time consuming but with FCPX ... said Christina Austin - CEO of Pixel Film Studios. , With the FCPX ... color grades to their footage. A LUT is a Lookup Table that contains a ...
(Date:5/28/2016)... ... ... and a half of planning the Multiple Pathways of Recovery Conference , CCAR is ... was held May 2 -4, 2016 at the Mystic Marriott Hotel & Spa . ... many pathways individuals use to get into and sustain their recovery. Pathways of recovery ...
(Date:5/27/2016)... Angeles, CA (PRWEB) , ... May 27, 2016 , ... ... of Health, so it is not surprising that bariatric surgery has received increased attention ... Business Journal explains. Of course, when it comes to weight loss, most people are ...
Breaking Medicine News(10 mins):
(Date:5/30/2016)... India , May 30, 2016 /PRNewswire/ ... market research report "Healthcare Biometrics Market by ... (Signature, Voice)), Multifactor, Multimodal), Application (Workforce Management), ... Forecast to 2021", published by MarketsandMarkets, the ... Million by 2021 from USD 1,182.6 Million ...
(Date:5/30/2016)... 2016 The global  parenteral ... billion by 2024, according to a new report ... rate, the growing malnutrition coupled with the prevalence ... tract diseases are expected to boost the market ... http://photos.prnewswire.com/prnh/20150105/723757 ) , The ...
(Date:5/30/2016)... 30, 2016 - DCGI grants limited approval ... Buerger,s disease - Stempeucel® becomes 5th off-the-shelf Stem cell ... world - Buerger,s Disease (also known as Thromboangiitis Obliterans) ... and Globally - Prevalence of Buerger,s Disease is ... 2 per 10,000 persons in the European Community & ...
Breaking Medicine Technology: